Advancements in biomanufacturing focus on flexibility and scale to meet rising demand for gene-edited therapies. Ori Biotech’s modular bioprocess platforms enable adaptable, Lego-like assembly of manufacturing components, integrating electroporation and fill-finish technologies to streamline workflows. Integration of cell-free protein synthesis with vesicle delivery systems enhances therapeutic protein production with improved stability and bioavailability. ProBio opened a U.S. flagship facility dedicated to plasmid and viral vector manufacturing under GMP conditions, reinforcing the commitment to accelerate cell and gene therapy clinical readiness and commercialization.